Literature DB >> 19118775

Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base.

Nalan Nese1, Gladell P Paner, Katherine Mallin, Jamie Ritchey, Andrew Stewart, Mahul B Amin.   

Abstract

On the basis of the National Cancer Data Base (NCDB), we describe the disease characteristics and use of conventional prognostic parameters in a hospital-based cohort of pathologically confirmed renal cell carcinomas (RCCs). Between 1993 and 1998, the NCDB obtained 149 424 cases of kidney (and renal pelvis) cancers from registries all over the United States. This database was queried for 47 909 histologically specified RCCs. Survival outcome was analyzed based on conventional clinical and pathologic parameters reported to the database (up to 2003). Renal cell carcinoma was more common in men (male-female ratio = 1.6:1). The mean age was 62.6 years. Most (66.6%) were organ-confined (stage I/II) at the time of diagnosis. The mean tumor size was 6.49 cm. The 5-year observed survival of RCC was 62.9% for male and 68.1% for female and was 81.0% for younger than 40 years old and 64.2% for older than 40 years old. The 5-year observed survival of RCC patients by the fifth edition 1997 American Joint Committee on Cancer TNM staging were stages I, 77.8%; II, 72.8%; III, 55.0%; and IV, 16.9%, demonstrating a dramatic decline in patient survival at stage IV. By reported pathologic grade, significant stratification was achieved in the observed survival for RCC overall irrespective of histologic subtypes (grade 1, 77.8%; 2, 69.6%; 3, 48.8%; and 4, 35.3% 5-year observed survival). These large NCDB data in RCC confirm the importance of pathologic evaluation of traditional prognostic parameters of stage and grade in RCC and is a powerful resource in defining cancer patient characteristics and analysis of prognostic variables that helps influence future cancer care planning and resource allocation.

Entities:  

Mesh:

Year:  2008        PMID: 19118775     DOI: 10.1016/j.anndiagpath.2008.10.002

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  5 in total

1.  Clinico-pathological analysis of renal cell carcinoma demonstrates decreasing tumour grade over a 17-year period.

Authors:  Gregory J Nason; Barry B McGuire; Michael E Kelly; Theodore M Murphy; Aisling T Looney; Damien P Byrne; David W Mulvin; David J Galvin; David M Quinlan; Gerald M Lennon
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862

2.  Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.

Authors:  Gerald Hj Mickisch; Björn Schwander; Bernard Escudier; Joaquim Bellmunt; José P Maroto; Camillo Porta; Stefan Walzer; Uwe Siebert
Journal:  Clinicoecon Outcomes Res       Date:  2011-01-25

3.  Establishment of predictive model for patients with kidney cancer bone metastasis: a study based on SEER database.

Authors:  Kun-Chi Hua; Yong-Cheng Hu
Journal:  Transl Androl Urol       Date:  2020-04

4.  Development and Validation of Prognostic Nomogram for Young Patients with Kidney Cancer.

Authors:  Shengwei Tian; Si Sun; Weipu Mao; Siwei Qian; Lei Zhang; Guangyuan Zhang; Bin Xu; Ming Chen
Journal:  Int J Gen Med       Date:  2021-09-01

Review 5.  Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Chao Wei; Shen Wang; Zhangqun Ye; Zhiqiang Chen
Journal:  Int Braz J Urol       Date:  2018 Mar-Apr       Impact factor: 1.541

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.